VC-backed Obalon Therapeutics rolls out IPO
San Diego-based Obalon Therapeutics, a developer of gastric balloon technology for weight loss therapy, has raised $75 million for its IPO after pricing its 5 million shares at $15 per share. The stock began trading October 6, 2016 on the NASDAQ under the ticker symbol "OBLN." UBS Investment Bank, Canaccord Genuity and Stifel are the lead underwriters. Obalon's backers included Axon Ventures, Mirae Asset Venture Investment, Striker Asia Opportunities Fund, Domain Associates, InterWest Partners and Okapi Venture Capital.
6 October 2016•2 mins read
